Market Overview 2025-2033

The Europe medical cannabis market size reached USD 2,586.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 12,652.9 Million by 2033, exhibiting a growth rate (CAGR) of 18.33% during 2025-2033. The market is growing due to increasing legalization, rising medical applications, and expanding research initiatives. Innovations in product development, regulatory support, and patient demand are driving expansion, making it a dynamic and evolving industry.

Key Market Highlights:

✔️ Rapid market growth driven by increasing legalization and acceptance of cannabis for medical use

✔️ Rising demand for cannabis-based treatments in pain management, neurology, and oncology

✔️ Expanding research and investment in pharmaceutical-grade cannabis production and innovation

Request for a sample copy of the report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample

Europe Medical Cannabis Market Trends and Drivers:

The European medical cannabis market is growing fast as more countries accept its use for treating chronic pain, mental health conditions, and neurological disorders. Germany, the UK, and Portugal are leading the way by making it easier for patients to get medical cannabis and setting new rules. In early 2024, Germany expanded its list of approved conditions, leading to a 40% jump in prescriptions. This shows how quickly the European medical cannabis market size is expanding. Support from the European Medicines Agency (EMA) has helped speed things up. By making the approval process simpler, the EMA is helping to build trust and encouraging more countries to adopt similar rules. Still, there's no consistent policy across Europe. France and Italy still require individual approvals, and Sweden is cautious.

These differences show why Europe needs clear, shared regulations to support a stronger medical cannabis market size in Europe. Growing medical cannabis also comes with stricter quality rules. Countries like Spain and the Netherlands now have high standards for growers, which improves product safety and attracts investors. In 2024, investments in the cannabis industry rose by 28%, helping boost the European medical cannabis market share. More patients are turning to cannabis as an alternative to regular medications. A 2024 survey showed that 62% of people with anxiety or PTSD felt better after using CBD-based treatments. With more people in Europe getting older—over 22% will be 65 or older by 2030—demand for safe and natural treatments is rising.

Germany has made big changes by covering medical cannabis under public health insurance. In 2024, over 1.2 million people used this option, especially older adults with long-term conditions. Younger patients are getting involved too. Services like Algea Care saw a 55% increase in patients under 35, many using cannabis to treat ADHD. Drug companies are taking note—Jazz Pharmaceuticals launched Sativex® in Spain and Poland to help people with multiple sclerosis. Supply is still an issue. In 2024, EU licenses for growing cannabis rose by 15%, but demand grew even faster—up 34%. This means Europe is still importing a lot, mainly from Canada and Israel. Companies are working together to meet demand. For example, Curaleaf from the UK bought Aurora Europe to grow its presence in Germany, Austria, and Switzerland. Denmark's Stenocare partnered with Poland's Herbionica to increase production by 2026.

Research is picking up. A 2024 study by the University of Leiden and Tilray looked at cannabis for nausea caused by chemotherapy. Results from this study could help shape future medical guidelines across Europe. Digital health platforms are also making it easier to get treatment. In Italy and Greece, telehealth providers like Cannify and Vayamed reported a 73% rise in online consultations. But prices are still a problem. In France, some patients pay up to €1,200 a month, while in the Netherlands it's closer to €300. These price differences are pushing some people toward unregulated sources, which raises safety concerns. Still, the outlook for the medical cannabis market size in Europe is positive. Rising costs—up 18% in 2024—are especially hard on small producers. But some companies are easing the pressure by going green.

Dutch grower Bedrocan now runs fully on renewable energy. Patient groups are also making a difference. In 2024, advocacy efforts led 11 EU countries to include medical cannabis in their public healthcare plans. Challenges remain. In parts of Eastern Europe, stigma still exists, and border rules can delay deliveries. But progress is steady. New tech, more personalized treatments, and better tools are moving the industry forward. As more people accept medical cannabis and regulations improve, Europe is on track for long-term growth—expanding access and increasing the European medical cannabis market share.

Europe Medical Cannabis Market Segmentation: 

The report segments the market based on product type, distribution channel, and region:

Study Period:

Base Year: 2024

Historical Year: 2019-2024

Forecast Year: 2025-2033

Breakup by Species:

  • Indica
  • Sativa
  • Hybrid

Breakup by Derivative:

  • Cannabidiol (CBD)
  • Tetrahydrocannabinol (THC)
  • Others

Breakup by Application:

  • Cancer
  • Arthritis
  • Migraine
  • Epilepsy
  • Others

Breakup by End Use:

  • Pharmaceutical Industry
  • Research and Development Centers
  • Others 

Breakup by Route of Administration:

  • Oral Solutions and Capsules
  • Smoking
  • Vaporizers
  • Topicals
  • Others

Breakup by Country:

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others

Competitive Landscape:

The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.

Contact Us: 

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145